Editor's note

This article was originally published on 15 April 2008 as part of the VacZine Analytics ExpertREACT series. It is reproduced here for archival purposes. Market conditions, pipeline statuses and regulatory positions described reflect the state of knowledge at that date.

Two very different cancer vaccine worlds

When examining the cancer vaccine landscape in 2008, it was essential to distinguish between two categorically different product types operating under very different commercial and scientific logics. First, prophylactic vaccines against oncogenic viruses - principally HPV - which had demonstrated the ability to generate blockbuster revenues through proven immunogenicity and clinical efficacy endpoints analogous to traditional vaccines. Second, therapeutic cancer vaccines designed to stimulate the immune system to attack existing tumour cells - a category with a lengthy history of clinical failures but continued commercial investment driven by the extraordinary theoretical commercial potential.

The HPV model: proof of commercial concept

Gardasil's first-year commercial performance had demonstrated that prophylactic cancer vaccines could achieve revenues comparable to the most successful traditional vaccines. With Cervarix expected to gain EU and US approval in 2008-2009, the HPV segment was becoming a genuine competitive arena, and the broader lesson - that clear oncogenic pathways with measurable prophylactic endpoints were commercially tractable - was influencing investment in other viral oncogenesis programmes.

HPV Vaccine Market 2008
~$2bn

Combined estimated global revenue for HPV vaccines in 2008, predominantly from Gardasil, with Cervarix approaching commercial launch in major markets

"Therapeutic cancer vaccines face a fundamentally different challenge from prophylactic ones - they must overcome tolerance, immunosuppression, and tumour escape simultaneously, while demonstrating a survival benefit that regulators will accept as sufficient for approval."